Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mattheos Bobos

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 18, 2021
AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group studyGeorge Zarkavelis, Epaminontas Samantas, Georgia-Angeliki Koliou, et al.
Journal of Oncology|January 13, 2010
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck CancerGeorge Fountzilas, Anna Kalogera-Fountzila, Sophia Lambaki, et al.
Annals of Translational Medicine|December 22, 2016
Coincidence of thymoma and breast cancer and in a 56-year-old female patientEvangelia Athanasiou, Electra Michalopoulou-Manoloutsiou, Mattheos Bobos, et al.
Anticancer Research|April 30, 2016
Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast CancerSotirios Lakis, Stefanos Dimoudis, Vassiliki Kotoula, et al.
American Journal of Cancer Research|December 2, 2016
Disease evolution and heterogeneity in bilateral breast cancerElena Fountzilas, Vassiliki Kotoula, Flora Zagouri, et al.
BMC Cancer|August 14, 2008
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory studyEvangelia Razis, Evangelos Briasoulis, Eleni Vrettou, et al.
Histology and Histopathology|March 26, 2015
Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) studyHelen P Kourea, Vassiliki Kotoula, Angelos Koutras, et al.
Cancer Genomics & Proteomics|April 26, 2019
Opposite Prognostic Impact of Single PTEN-loss and <i>PIK3CA</i> Mutations in Early High-risk Breast CancerGeorgios Lazaridis, Vassiliki Kotoula, Eleni Vrettou, et al.
Clinical Breast Cancer|December 15, 2018
Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient OutcomeVassiliki Kotoula, Kalliopi Tsakiri, Georgia-Angeliki Koliou, et al.
Journal of Translational Medicine|May 18, 2016
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerHelen Gogas, Vassiliki Kotoula, Zoi Alexopoulou, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Acta Oncologica (Stockholm, Sweden)|May 18, 2021
AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group studyGeorge Zarkavelis, Epaminontas Samantas, Georgia-Angeliki Koliou, et al.
Journal of Oncology|January 13, 2010
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck CancerGeorge Fountzilas, Anna Kalogera-Fountzila, Sophia Lambaki, et al.
Annals of Translational Medicine|December 22, 2016
Coincidence of thymoma and breast cancer and in a 56-year-old female patientEvangelia Athanasiou, Electra Michalopoulou-Manoloutsiou, Mattheos Bobos, et al.
Anticancer Research|April 30, 2016
Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast CancerSotirios Lakis, Stefanos Dimoudis, Vassiliki Kotoula, et al.
American Journal of Cancer Research|December 2, 2016
Disease evolution and heterogeneity in bilateral breast cancerElena Fountzilas, Vassiliki Kotoula, Flora Zagouri, et al.
BMC Cancer|August 14, 2008
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory studyEvangelia Razis, Evangelos Briasoulis, Eleni Vrettou, et al.
Histology and Histopathology|March 26, 2015
Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) studyHelen P Kourea, Vassiliki Kotoula, Angelos Koutras, et al.
Cancer Genomics & Proteomics|April 26, 2019
Opposite Prognostic Impact of Single PTEN-loss and <i>PIK3CA</i> Mutations in Early High-risk Breast CancerGeorgios Lazaridis, Vassiliki Kotoula, Eleni Vrettou, et al.
Clinical Breast Cancer|December 15, 2018
Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient OutcomeVassiliki Kotoula, Kalliopi Tsakiri, Georgia-Angeliki Koliou, et al.
Journal of Translational Medicine|May 18, 2016
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerHelen Gogas, Vassiliki Kotoula, Zoi Alexopoulou, et al.
Pageof 10